At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,438 enrolled
Drug / intervention
LCZ696 +3 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating LCZ696, Olmesartan, and 2 other interventions for Essential Hypertension. Completed, enrolled 1,438 participants across 50 sites in 7 countries.
Detailed Summary
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesChina, Hong Kong, Philippines, Singapore, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedFeb 7, 2013
Enrollment StartApr 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.4 years ago
Interventions
LCZ696drug
LCZ696 200 mg tablet
Olmesartandrug
Olmesartan 20 mg capsule
Placebo of LCZ696drug
Placebo tablet of LCZ696 200 mg once daily
Placebo of Olmesartandrug
Placebo capsule of olmesartan 20 mg once daily